| Literature DB >> 20828814 |
Sarah A Holstein1, Raymond J Hohl.
Abstract
Myeloma is characterized by the overproduction and secretion of monoclonal protein. Inhibitors of the isoprenoid biosynthetic pathway (IBP) have pleiotropic effects in myeloma cells. To investigate whether IBP inhibition interferes with monoclonal protein secretion, human myeloma cells were treated with specific inhibitors of the IBP or prenyltransferases. These studies demonstrate that agents that inhibit Rab geranylgeranylation disrupt light chain trafficking, lead to accumulation of light chain in the endoplasmic reticulum, activate the unfolded protein response pathway and induce apoptosis. These studies provide a novel mechanism of action for IBP inhibitors and suggest that further exploration of Rab-targeted agents in myeloma is warranted.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20828814 PMCID: PMC3038195 DOI: 10.1016/j.leukres.2010.08.008
Source DB: PubMed Journal: Leuk Res ISSN: 0145-2126 Impact factor: 3.156